Consort Medical Takes Nearly 20 Percent Stake in Atlas Genetics | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Consort Medical, a UK-based manufacturer of drug delivery and medical device technologies, has acquired a roughly 20 percent stake in Atlas Genetics for £1.1 million ($1.8 million).

The firms also announced an alliance, under which Consort's Bespak division will design disposable test cards that will be part of Atlas' rapid, point-of-care molecular diagnostics system. Consort said that it also has received long-term manufacturing rights for the cards.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.